Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2022-04-25 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
独立董事关于第五届董事会第二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on a specific board meeting item regarding asset impairment. It references compliance with regulatory guidelines and accounting standards but does not contain financial statements or comprehensive financial data. The document is short (529 characters) and focuses on governance and board-level opinions rather than full financial reporting. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management matters, including independent director opinions on board decisions.
2022-04-25 Chinese
2021年度募集资金存放与实际使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised through share issuance, including specifics on amounts raised, usage, changes in investment projects, and compliance with regulatory approvals. It references approvals from the China Securities Regulatory Commission and includes detailed financial figures related to fundraising and fund usage. The document is titled as a "专项报告" (special report) on the storage and use of raised funds for the year 2021. This type of document corresponds to a Capital/Financing Update, as it focuses on fundraising activities, fund allocation, and compliance with regulatory requirements related to capital raised. It is not an annual report, earnings release, or other types of filings. The length and detail confirm it is a substantive report, not just an announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-04-25 Chinese
第五届监事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of the company 福安药业 regarding the approval of an asset impairment provision. It includes details about the meeting date, attendance, and voting results. The content focuses on internal board decisions and approvals rather than financial statements or detailed financial performance. The document length is short (558 characters) and it is an official announcement of a board meeting resolution. This fits best under Board/Management Information (MANG) as it relates to board decisions and governance matters, not a full audit report or annual report. Therefore, the classification is MANG with high confidence.
2022-04-25 Chinese
2021年度募集资金存放与实际使用情况审核报告
Audit Report / Information Classification · 95% confidence The document is titled as an audit report on the 2021 annual fundraising funds deposit and usage situation of 福安药业（集团）股份有限公司. It is issued by an accounting firm and includes detailed audit opinions, responsibilities, and verification of the fundraising funds usage. The content focuses on the audit of the company's fundraising funds usage, compliance with regulatory requirements, and includes financial figures related to fundraising and usage. It is not a full annual report but a standalone audit report specifically on fundraising funds usage. Therefore, it fits the category of Audit Report / Information (AR). The document length is sufficient and contains substantive audit content, not just an announcement or certification. FY 2021
2022-04-25 Chinese
关于为子公司申请银行授信融资提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company providing guarantees for bank credit financing to its subsidiaries. It includes details about the guarantee amounts, the subsidiaries involved, financial data of the subsidiaries, and approvals from the board and independent directors. There is no indication that this is a full financial report, audit report, or earnings release. The document is a formal announcement about financing guarantees, which fits the category of Capital/Financing Update (CAP). The document length is under 5,000 characters, but it contains substantive information about financing guarantees rather than just announcing a report publication. Therefore, it is classified as a Capital/Financing Update.
2022-04-25 Chinese
只楚药业资产评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an "资产评估报告" (Asset Valuation Report) specifically for goodwill impairment testing related to 福安药业集团烟台只楚药业有限公司. It contains detailed valuation methodology, financial data, asset and liability breakdowns, and an evaluation conclusion of recoverable value as of December 31, 2021. The report is prepared by an asset valuation company and is intended to support the goodwill impairment test for the company. This is a standalone asset valuation report, not a full annual or interim financial report, nor an announcement or certification. It fits the definition of an Audit Report / Information (AR) as it provides applied accounting principles and valuation results related to impairment testing, separate from a full annual report. The document length is substantial (15,000 characters), and it contains substantive financial and valuation data, not merely an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2021
2022-04-25 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.